KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Receivables (2016 - 2025)

Pacira BioSciences has reported Receivables over the past 16 years, most recently at $124.1 million for Q4 2025.

  • Quarterly results put Receivables at $124.1 million for Q4 2025, up 9.5% from a year ago — trailing twelve months through Dec 2025 was $124.1 million (up 9.5% YoY), and the annual figure for FY2025 was $124.1 million, up 9.5%.
  • Receivables for Q4 2025 was $124.1 million at Pacira BioSciences, up from $115.3 million in the prior quarter.
  • Over the last five years, Receivables for PCRX hit a ceiling of $124.1 million in Q4 2025 and a floor of $50.0 million in Q3 2021.
  • Median Receivables over the past 5 years was $98.7 million (2022), compared with a mean of $95.8 million.
  • Biggest five-year swings in Receivables: skyrocketed 87.04% in 2022 and later rose 1.2% in 2023.
  • Pacira BioSciences' Receivables stood at $96.3 million in 2021, then rose by 2.16% to $98.4 million in 2022, then rose by 7.28% to $105.6 million in 2023, then rose by 7.34% to $113.3 million in 2024, then grew by 9.5% to $124.1 million in 2025.
  • The last three reported values for Receivables were $124.1 million (Q4 2025), $115.3 million (Q3 2025), and $114.4 million (Q2 2025) per Business Quant data.